Jade Biosciences, Inc. Debt Securities, Available-for-sale, Unrealized Loss
Jade Biosciences, Inc. (JBIO) reported Debt Securities, Available-for-sale, Unrealized Loss of $785.00 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2022-08-15
- Jade Biosciences, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-06-30 was $141.00K.
- Jade Biosciences, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-03-31 was $644.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|
| 2022-06-30 | $141.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $785.00K 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $644.00K 10-Q · filed 2022-05-16 | ||
| 2021-12-31 | $68.00K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |